Indoor bioaerosols and asthma: Overview, implications, and mitigation strategies.

IF 11.4 1区 医学 Q1 ALLERGY
Karen C Dannemiller, Laura A Conrad, Sarah R Haines, Yvonne J Huang, Linsey C Marr, Jeffrey A Siegel, Sumaiya Hassan, Jon C King, Aaron J Prussin, Austin Shamblin, Matthew S Perzanowski
{"title":"Indoor bioaerosols and asthma: Overview, implications, and mitigation strategies.","authors":"Karen C Dannemiller, Laura A Conrad, Sarah R Haines, Yvonne J Huang, Linsey C Marr, Jeffrey A Siegel, Sumaiya Hassan, Jon C King, Aaron J Prussin, Austin Shamblin, Matthew S Perzanowski","doi":"10.1016/j.jaci.2024.11.027","DOIUrl":null,"url":null,"abstract":"<p><p>Aerosolized particles with a biological origin are called bioaerosols. Bioaerosols from plants, animals, fungi, bacteria, and viruses are an important class of environmental exposures that are clinically relevant to asthma. However, there are important differences in the pathways by which various bioaerosols affect asthma. Additionally, differences in individual susceptibility to different bioaerosols affect exposure reduction and mitigation strategies. Strategies to reduce exposures to potential triggers of asthma are routinely considered as part of standard clinical care and asthma management guidelines. Ventilation standards in buildings may reduce bioaerosol exposure for everyone, but they are not necessarily designed specifically to protect patients with asthma. Direct measurement of a bioaerosol is not generally necessary for practical applications where the relevant source of the bioaerosol has been identified. Different types of bioaerosols can be controlled with similar strategies that prioritize source control (eg, reducing resuspension, integrated pest management, controlling moisture), and these can be supplemented by enhancing air filtration. The goal of this review is to summarize the latest information on bioaerosols, including allergens, fungi, bacteria, and viruses, that have been associated with adverse asthma outcomes and to discuss mitigation options.</p>","PeriodicalId":14936,"journal":{"name":"Journal of Allergy and Clinical Immunology","volume":" ","pages":""},"PeriodicalIF":11.4000,"publicationDate":"2024-11-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Allergy and Clinical Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1016/j.jaci.2024.11.027","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ALLERGY","Score":null,"Total":0}
引用次数: 0

Abstract

Aerosolized particles with a biological origin are called bioaerosols. Bioaerosols from plants, animals, fungi, bacteria, and viruses are an important class of environmental exposures that are clinically relevant to asthma. However, there are important differences in the pathways by which various bioaerosols affect asthma. Additionally, differences in individual susceptibility to different bioaerosols affect exposure reduction and mitigation strategies. Strategies to reduce exposures to potential triggers of asthma are routinely considered as part of standard clinical care and asthma management guidelines. Ventilation standards in buildings may reduce bioaerosol exposure for everyone, but they are not necessarily designed specifically to protect patients with asthma. Direct measurement of a bioaerosol is not generally necessary for practical applications where the relevant source of the bioaerosol has been identified. Different types of bioaerosols can be controlled with similar strategies that prioritize source control (eg, reducing resuspension, integrated pest management, controlling moisture), and these can be supplemented by enhancing air filtration. The goal of this review is to summarize the latest information on bioaerosols, including allergens, fungi, bacteria, and viruses, that have been associated with adverse asthma outcomes and to discuss mitigation options.

室内生物气溶胶和哮喘:概述、影响和缓解策略。
具有生物来源的雾化颗粒称为生物气溶胶。来自植物、动物、真菌、细菌和病毒的生物气溶胶是一类重要的环境暴露,在临床上与哮喘有关。然而,各种生物气溶胶影响哮喘的途径存在重要差异。此外,个体对不同生物气溶胶易感性的差异影响了减少和缓解暴露的战略。减少暴露于哮喘潜在诱因的策略通常被认为是标准临床护理和哮喘管理指南的一部分。建筑物的通风标准可以减少每个人的生物气溶胶暴露,但不一定是专门为保护哮喘患者而设计的。在生物气溶胶的相关来源已经确定的情况下,在实际应用中一般不需要直接测量生物气溶胶。不同类型的生物气溶胶可以通过类似的策略进行控制,优先考虑源头控制(例如减少再悬浮、综合虫害管理、控制湿度),并可以通过加强空气过滤来补充。本综述的目的是总结生物气溶胶的最新信息,包括与哮喘不良结局相关的过敏原、真菌、细菌和病毒,并讨论缓解方案。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
25.90
自引率
7.70%
发文量
1302
审稿时长
38 days
期刊介绍: The Journal of Allergy and Clinical Immunology is a prestigious publication that features groundbreaking research in the fields of Allergy, Asthma, and Immunology. This influential journal publishes high-impact research papers that explore various topics, including asthma, food allergy, allergic rhinitis, atopic dermatitis, primary immune deficiencies, occupational and environmental allergy, and other allergic and immunologic diseases. The articles not only report on clinical trials and mechanistic studies but also provide insights into novel therapies, underlying mechanisms, and important discoveries that contribute to our understanding of these diseases. By sharing this valuable information, the journal aims to enhance the diagnosis and management of patients in the future.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信